EMA Withdrawn: Unituxin (Dinutuximab) — United Therapeutics Europe Ltd

View source ↗

Summary

EMA has withdrawn Unituxin (dinutuximab) from the market in Europe.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroblastoma

Drugs mentioned

• UNITUXIN (dinutuximab)

Snippet

Status: Withdrawn. Therapeutic area: Neuroblastoma. MAH: United Therapeutics Europe Ltd. Decision date: 20/03/2017